Search

Displaying results 4731 - 4740 of 5449 in total
  1. Drug

    Ammonium molybdate

    go.drugbank.com/drugs/DB11128
    Investigational

    It is intravenously administered as an additive to solutions for Total Parenteral Nutrition (TPN).

  2. Drug

    Pimicotinib

    go.drugbank.com/drugs/DB18972
    Investigational

    It was initially developed by Abbisko Therapeutics Co in collaboration with Merck KGaA. [L53748] Pimicotinib was granted Fast Track Designation in December 2023 by the FDA. [L53753]

  3. Drug

    R673

    go.drugbank.com/drugs/DB05466
    Experimental

    R673 is a novel NK1 antagonist that penetrates the blood-brain barrier, has excellent safety and tolerability and shows low P450-based drug interaction potential. The phase II program for treatment of depression and anxiety is ongoing in...

  4. Drug

    13-deoxydoxorubicin

    go.drugbank.com/drugs/DB05706
    Investigational

    GPX-100 is an anthracycline anticancer drug that belongs to the family of drugs called antitumor antibiotics.

  5. Drug

    MLN3897

    go.drugbank.com/drugs/DB06505
    Experimental

    MLN3897, a novel CCR1 inhibitor, disrupts osteoclast formation and blocks the interaction between multiple myeloma cells and osteoclasts.

  6. Drug

    Amubarvimab

    go.drugbank.com/drugs/DB16493
    Investigational

    Amubarvimab (BRII-196) was under investigation in clinical trials (NCT04691180 and NCT04787211) to treat COVID-19, focusing on its safety, tolerability, and efficacy.

  7. Drug

    Seletracetam

    go.drugbank.com/drugs/DB05885
    Investigational

    It binds to the same target as levetiracetam but with higher affinity and has shown potent seizure suppression in models of acquired and genetic epilepsy with high CNS tolerability. … It is predicted to have low drug-drug interactions and inhibition or induction of any major human metabolizing enzymes. Seletracetam was in Phase II clinical trials under the supervision of the U.S.

  8. Drug

    VPM4001

    go.drugbank.com/drugs/DB05089
    Experimental

    Interferon-γ enhances presentation of tumour antigens, whereas interleukin-2 stimulates T cells. … It consists of irradiated human LNCaP cells that have been genetically modified to permanently secrete interferon-γ and interleukin-2 (LNCaP/IL-2/IFN-γ).

  9. Drug

    TB-402

    go.drugbank.com/drugs/DB06050
    Investigational

    It is expected to be developed as a potential treatment to prevent blood clot formation in connection with certain types of heart arrhythmia, such as atrial fibrillation.

  10. Drug

    Bisegliptin

    go.drugbank.com/drugs/DB06127
    Investigational

    It is an orally active, dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucose levels by blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion